drugset / Trial / NCT04502342

Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients

NCT04502342

RandomizedParallel-groupOpen-labelTreatment

Summary

The phase II clinical trial, with three arms and at rate of 10 patients per arm, received the approval of the National Committee for Ethics and Health Research. This is a non inferiority test aimed to compare the efficacy and safety in add on to Azithromycin, an antimalarial drug, a treatment combination of the antimalrial drug with an antiviral phytomedicine versus Hydroxychloroquine in COVID-19 patients without complications. During the treatment, viral clearance, adverse effects related to treatment, and symptoms progression will be assessed on days 3, 6 and 14. Clinical, paraclinical and laboratory tests will be performed throughout the 3-month trial. Ethical and deontological considerations will be applied.

Timeline

Start
2020-06-01
Primary completion
2020-08-30
Completion
2020-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 100 mg Oral
Subject Asen Unknown 350 mg Oral
Subject Hydroxychloroquine Small molecule 200 mg Oral
Subject amodiaquine Other / unclassified 250 mg Oral
Background Azithromycin Small molecule 250 mg Oral

Indications